Talking Medicines is highlighting how pharmaceutical companies can improve product launches by measuring whether doctors understand and retain key product messages.
Clinical evidence alone does not guarantee commercial success. Doctors need to understand a medicine’s benefits, its role in treatment and how it should be used. Unclear messaging can affect prescribing decisions and limit uptake.
The first two years after launch are particularly important, as pharmaceutical companies work to establish product positioning and build confidence among healthcare professionals.
Talking Medicines has developed its Message Resonance Score to assess how doctors respond to pharmaceutical messaging. It measures understanding, clarity of treatment positioning and confidence in using a medicine.
The company’s DrugVoice platform analyses real-world conversations to provide insights into how medicines and their supporting messages are understood. These findings can help pharmaceutical businesses identify communication gaps and adjust their launch strategies.
The approach is intended to help companies assess whether their marketing communicates clinical evidence effectively, particularly in complex treatment areas such as oncology, immunology and rare diseases.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
